These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
635 related articles for article (PubMed ID: 11381372)
1. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
3. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265 [TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
5. In search of a positive immunohistochemical marker for mesothelioma: an update. Ordóñez NG Adv Anat Pathol; 1998 Jan; 5(1):53-60. PubMed ID: 9868512 [No Abstract] [Full Text] [Related]
6. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236 [TBL] [Abstract][Full Text] [Related]
7. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Ordóñez NG Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717 [TBL] [Abstract][Full Text] [Related]
8. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584 [TBL] [Abstract][Full Text] [Related]
9. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Roberts F; Harper CM; Downie I; Burnett RA Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073 [TBL] [Abstract][Full Text] [Related]
11. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
12. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Comin CE; Saieva C; Messerini L Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535 [TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies]. Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912 [TBL] [Abstract][Full Text] [Related]
14. Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice. Mohammad T; Garratt J; Torlakovic E; Gilks B; Churg A Am J Surg Pathol; 2012 Oct; 36(10):1503-8. PubMed ID: 22982894 [TBL] [Abstract][Full Text] [Related]
15. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250 [TBL] [Abstract][Full Text] [Related]
18. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268 [TBL] [Abstract][Full Text] [Related]
19. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163 [TBL] [Abstract][Full Text] [Related]
20. Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma. Khalidi HS; Medeiros LJ; Battifora H Am J Clin Pathol; 2000 May; 113(5):649-54. PubMed ID: 10800396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]